Dianthus Therapeutics DNTH Preclinical Study Activity Costs — Claseprubart Program Related Expenses

Similar metrics at other companies

NUVLDiscovery Programs — Direct Expenses Related To Program

$2.8M+31.4%

PRAXOther early stage assets — Program-specific expenses

$3.24M+193%

ROIVBrepocitinib — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

$14.34M+9.7%

TRA

TRAXPreclinical And Other Unallocated Costs — Research And Development Expense Reversal Excluding Acquired In Process Cost

$3.3M-16.2%

RYTMSingle reportable segment — Preclinical, clinical and development expense

$18.51M-7.3%

SRRKEarly Research — Research And Development Expense

$1.21M-16.8%

Questions, answered.

What is Dianthus Therapeutics's preclinical study activity costs — claseprubart program related expenses?

Dianthus Therapeutics (DNTH) reported preclinical study activity costs — claseprubart program related expenses of $320K in Q1 2026.

What does preclinical study activity costs — claseprubart program related expenses mean?

This metric represents the direct research and development expenditures allocated to the preclinical development phase of the Claseprubart therapeutic program. It captures costs associated with laboratory testing, animal studies, and early-stage development activities necessary to advance the candidate toward clinical trials. Monitoring these costs provides insight into the company's capital allocation toward specific pipeline assets and the intensity of its early-stage R&D efforts.